Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07089901

Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment

Tobacco use is a chronic relapsing condition. That is, even with state-of-the-art treatment, >70% of smoking cessation attempts end in a return to regular smoking. Research demonstrates that everyday environments associated with smoking trigger craving for cigarettes, provoke smoking, and lead to relapse. However, despite this knowledge, understanding of environmental correlates of smoking has been limited by a reliance on self-report, leading to imprecise information about the physical environments in which people live. To overcome this challenge, the research team has pioneered the development of digital envirotyping, which uses digital tools (e.g., sensors, cameras, artificial intelligence) to efficiently and accurately characterize and categorize environments with the goal of identifying environmental markers of behavior and health. Foundational to the digital envirotyping research is computer vision (CV), a type of artificial intelligence (AI) that enables computer systems to recognize objects and scenes in digital images, mimicking how humans perceive and understand visual information. With CV researchers can extract detailed and accurate information (i.e., objects and location types) about the everyday environments of people who smoke (PWS) and relate that information to smoking behavior. After validating the use of CV, the researchers used CV to develop enviromarkers of relapse risk. Importantly, they identified a novel enviromarker in which people at greater risk for relapse when they quit are exposed to a more consistent level of environment-related smoking risk as they move between their smoking and nonsmoking environments.

Research is now needed to advance digital envirotyping and enviromarker development in the field of tobacco addiction. The study will recruit a diverse, national sample of n=500 adults who are interested in quitting smoking. For two weeks prior to quitting, they will undergo photoEMA in which they will take two pictures of their current environment when they smoke, and randomly 10 times per day resulting in >300,000 images total. Cessation will be supported by nicotine replacement therapy (i.e., nicotine patch). The primary clinical outcome will be days to relapse. Specific aims are to (1) further develop, refine, and validate methods for efficient digital envirotyping at scale, (2) leverage CV and AI approaches to develop enviromarkers of smoking relapse, and (3) conduct analyses to increase understanding of environmental smoking risk in women and individuals with low socioeconomic status.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Duke University Medical Center

Durham, North Carolina, 27706, United States

Location status: Recruiting

Location contact

Laura E Van Althuis, MHA

CONTACT

9196684312

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 21 years of age or older;
  • Smoke ≥ 10 cigarettes/day
  • Smoking daily for ≥ 2 years, with a stable smoking pattern for the past 6 months;
  • Intention to quit smoking and set a target quit date in the next 1 month;
  • Have an iPhone or Android smartphone capable of running the photoEMA and iCO software
  • Positive Urine Cotinine Test

Exclusion criteria

  • Pregnant, breastfeeding, or planning to become pregnant during the course of the study;
  • Currently in smoking cessation treatment or current use of smoking cessation products;
  • Regular use (i.e. >9 days/month) of non-cigarette nicotine-containing products (e.g. cigarillos, e-cigarettes);
  • Anticipating major life changes (e.g. new job, birth of a child) during the course of the study;
  • Unstable medical conditions;
  • Contraindication for nicotine replacement therapy.

Treatment and study plan

transdermal nicotine replacement therapy

Drug

All participants will receive transdermal nicotine replacement therapy (21 mg. patches)

Other names: NRT, nicotine patch

Primary outcomes

  1. Average number of days to smoking relapse

    Time frame: From quit date to 6-month follow-up (about 6.5 months)

    Participants will self-report smoking from quit date to the 6-month follow-up visit. Days to relapse will be defined as the first of seven consecutive days of smoking.

Secondary outcomes

  1. Number of participants who self-report 7-day point prevalence abstinence

    Time frame: 1-month follow-up (around 1.5 months after beginning treatment)

    7-day point prevalence abstinence is defined as no smoking in the prior 7 days.

  2. Number of participants who self-report 7-day point prevalence abstinence

    Time frame: 3-month follow-up (around 3.5 months after beginning treatment)

    7-day point prevalence abstinence is defined as no smoking in the prior 7 days.

  3. Number of participants who self-report 7-day point prevalence abstinence

    Time frame: 6-month follow-up (around 6.5 months after beginning treatment)

    7-day point prevalence abstinence is defined as no smoking in the prior 7 days.

Study contacts

Contact information is provided by the study sponsor or research team.

Jasmin Walia

CONTACT

[email protected]

919-668-0983

Laura Van Althuis, MHA

CONTACT

[email protected]

919-668-4312

Sponsors and collaborators

Lead sponsor

Duke University

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Acronym: DEDUCE

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Jul 28, 2025
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.